[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-tumors-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-tumors-adult":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,41,105,131,153,176,197,221,242,271,292,311,340,361],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100505477","phase-1-hf158k1-in-patients-with-her-2-expressing-advanced-solid-tumors-100505477",false,"NCT05861895","HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors","A Phase 1 Clinical Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of HF158K1 in Participants With HER-2 Expressing Advanced Solid Tumors","Inclusion Criteria:\n\n1. Voluntary to participate and sign ICF.\n2. Age ≥ 18 and ≤ 75 years.\n3. Unresectable or metastatic advanced solid tumors with HER-2 expression (IHC 3+, 2+, or 1+).\n4. ECOG score 0-1.\n5. Expected survival ≥ 6 months.\n6. At least one measurable lesion per RECIST v1.1.\n7. Adequate organ function: ANC ≥ 1.5×10⁹\u002FL, LYM ≥ 1.0×10⁹\u002FL, PLT ≥ 90×10⁹\u002FL, HGB ≥ 8.0 g\u002FdL; APTT ≤ 1.5×ULN, INR ≤ 1.5; TBIL ≤ 1.5×ULN, ALT\u002FAST ≤ 2.5×ULN (≤ 5×ULN if liver metastases); CrCl ≥ 30 mL\u002Fmin; LVEF ≥ 50%.\n8. Agreement to use effective contraception.\n\nExclusion Criteria:\n\n1. Cumulative doxorubicin dose ≥ 350 mg\u002Fm² or prior anthracycline-induced cardiotoxicity.\n2. Current use of immunosuppressants or systemic corticosteroids (\\> 10 mg\u002Fday prednisone).\n3. Prior anti-tumor therapy \\\u003C 2 weeks (4 weeks for nitrosourea\u002Fmitomycin C).\n4. Symptomatic CNS metastases.\n5. Unresolved AEs from prior therapy \\> Grade 1.\n6. Serious cardiovascular diseases (thromboembolic events within 3 months, NYHA III-IV, ACS within 6 months, or uncontrolled hypertension).\n7. Active infection or unexplained fever \\> 38.5°C.\n8. HIV, active HBV or HCV.\n9. Pregnant or breastfeeding.","ALL","18 Years","75 Years",{"count":20,"type":21},84,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.",[27],"Solid Tumors, Adult","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":32},"2023-12-12",{"date":36,"type":21},"2027-12-23",{"name":38,"class":39},"HighField Biopharmaceuticals Corporation","INDUSTRY",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100498275","phase-1-first-in-human-study-of-tersolisib-stx-478-as-monotherapy-and-in-combination-with-other-antineoplastic-agents-in-participants-with-advanced-solid-tumors-100498275","NCT05768139","First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","PIKALO-1","Key Inclusion Criteria:\n\n* Has an advanced or refractory solid tumor malignancy that is metastatic or locally advanced and unresectable (as specified by Cohort)\n* Has a new or recent tumor biopsy (collected at screening, if feasible) or will provide an adequate tissue sample prior to screening\n* Has a tumor that harbors a documented PI3Kα mutation (cohort specific criterion for cohort-specific mutation types)\n* Is ≥18 years of age at the time of signing the ICF\n* Has an ECOG performance status score of 0 or 1 at screening\n* Has adequate organ function as defined per protocol\n\nKey Exclusion Criteria:\n\n* Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied\n* Has symptomatic brain or spinal metastases\n* Has an established diagnosis of uncontrolled diabetes mellitus (defined as HbA1c ≥8% and\u002For FBG ≥140 mg\u002FdL \\[7.7 mmol\u002FL\\] and\u002For requiring or required insulin).\n* Has had prior treatment with PI3K\u002FAKT\u002FmTOR inhibitor(s), except in certain circumstances\n* Has had treatment with any local or systemic antineoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to the initiation of study treatment up to a maximum washout period of 28 days. Endocrine therapy does not require a washout period if the patient is enrolling in a cohort with the same combination endocrine therapy.\n* Has toxicities from previous anticancer therapies that have not resolved to baseline levels or CTCAE grade ≤1, with the exception of alopecia and peripheral neuropathy.\n* Has had radiotherapy within 14 days before the initiation of study treatment",{"count":50,"type":21},880,[24,52],"PHASE2","Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1\u002F2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations.\n\nPart 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4\u002F6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer.\n\nEach study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.",[55,27],"Breast Cancer",[57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94],"Breast Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","HER2-negative breast cancer","HR-positive breast cancer","Gynecologic cancer","Endometrial cancer","Ovarian cancer","Cervical cancer","Head and neck cancer","Head and neck squamous cell carcinoma","Fulvestrant","Antineoplastic Agents","PI3Kα","PI3K alpha","PI3Kα mutation","Alpelisib","STX-478","PI3Kα inhibitor","Estrogen Receptor Antagonists","Estrogen Antagonists","Hormone Receptor Antagonists","Hormone Antagonists","Hormones, Hormone Substitutes, and Hormone Antagonists","Physiological Effects of Drugs","Palbociclib","Ribociclib","PIK3CA","PIK3CA mutation","Aromatase inhibitor","Letrozole","Anastrozole","Exemestane","Imlunestrant","Inavolisib","Capivasertib","Abemaciclib","2026-06-03",{"date":97,"type":32},"2026-06-04",{"date":99,"type":32},"2023-04-17",{"date":101,"type":21},"2030-07",{"name":103,"class":39},"Eli Lilly and Company",65,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100410202","phase-1-imaging-of-solid-tumors-using-fap-2286-100410202","NCT04621435","Imaging of Solid Tumors Using FAP-2286","Inclusion Criteria:\n\n1. Age \\>= 18 years.\n2. Histopathologically confirmed solid tumors in one of the following cohorts:\n\n   a. Cohort 1 (n=11): measurable disease is not required for this cohort.\n\n   i. Agnostic to tumor type.\n\n   b. Cohort 2 (n=95): Metastatic disease present on conventional imaging defined as having RECIST 1.1 measurable disease or multiple bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.\n\n   i. Pathologically confirmed breast cancer, pancreatic adenocarcinoma, sarcoma, castrate-resistant prostate cancer, bladder cancer, colon cancer, or other cancer type.\n\n   c. Cohort 3 (n=85): No evidence of metastatic disease as defined as the absence of RECIST 1.1 measurable disease or bone metastases. Note: Presence of absence of metastatic disease for eligibility determination will be assessed by reviewing medical records. Screening imaging will not be conducted for this study.\n\n   i. Participants can be imaged at initial staging with what is judged by the treating physician to be high risk disease and where the presence of metastatic disease would greatly impact treatment planning and prognosis. Participants may also be imaged after therapy (surgery, chemotherapy or radiation therapy) if in the determination of the treating physician or investigator there is a high risk of disease recurrence that would also impact treatment plan and\u002For prognosis.\n\n   ii. Pathologically confirmed head and neck cancer, bladder cancer, or other cancer type.\n3. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.\n2. Known pregnancy.",{"count":112,"type":21},191,[24],"This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.",[27,116],"Metastatic Cancer",[118,119,120],"PET","68Ga-FAP-2286","64Cu-FAP-2286","2026-06-02",{"date":97,"type":32},{"date":124,"type":32},"2020-12-14",{"date":126,"type":21},"2026-12-31",{"name":128,"class":129},"Thomas Hope","OTHER",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100610489","phase-1-a-phase-a-study-of-hmpl-a251-in-participants-with-advanced-or-metastatic-her2-expressing-solid-tumors-100610489","NCT07228247","A Phase Ⅰ\u002FⅡa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","A Phase Ⅰ\u002FⅡa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A251 in Participants With Advanced or Metastatic HER2-Expressing Solid Tumors","Inclusion Criteria:\n\n1. Histologically confirmed unresectable advanced or metastatic disease.\n2. Have at least one measurable lesion per RECIST v1.1;\n3. Life expectancy ≥ 12 weeks;\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;\n5. Weight ≥ 35 kg;\n\nExclusion Criteria:\n\n1. An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.\n2. Use of strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;\n3. Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);\n4. Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;\n5. Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;\n6. Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and\u002For complications from the intervention prior to the first dose of study drug(s);",{"count":139,"type":21},147,[24,52],"This is a first-in-human (FIH), phase Ⅰ\u002FⅡa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.",[27],"2026-05-25",{"date":145,"type":32},"2026-05-27",{"date":147,"type":32},"2025-12-16",{"date":149,"type":21},"2028-12-31",{"name":151,"class":39},"Hutchmed",16,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100472322","phase-1-gt101-injection-for-the-treatment-of-metastatic-or-recurrent-solid-tumors-100472322","NCT05430373","GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors","A Single-arm Phase I Clinical Study of GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors","Inclusion Criteria:\n\n* 1\\. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board\u002FIndependent Ethics Committee (IRB\u002FIEC), must have the ability to understand the requirements of the study;\n* 2.Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor;\n* 3.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. The separated tissues mass weighing ≥1.0g (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible;\n\nExclusion Criteria:\n\n* 1\\. Patients who have symptomatic and\u002For untreated CNS metastases (Except stable brain metastases, no medication required within 3 months, no hormone dependence);\n* 2.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\\>10 mg\u002Fday of prednisone or equivalent hormone);\n* 3\\. Arterial\u002Fvenous thrombotic events within 6 months prior to surgical operation, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring;\n* 4.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever \\> 38.5℃ occurring during the screening period, except for tumor fever;\n* 5\\. Patients who have refractory or intractable epilepsy, poorly controlled hydrothorax, hydrops abdominis, active gastrointestinal bleeding or IL-2 contraindications;\n* 6\\. Participate in other clinical trials within 28 days prior to the first dose of this study, or planning to participate in this study and other clinical trials at the same time;\n* 7\\. Patients who have received allogeneic bone marrow transplantation or an organ allograft;\n* 8.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);","70 Years",{"count":162,"type":21},31,[24],"This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period.\n\nThe study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an \"autologous tumor-infiltrating lymphocyte therapy\" regimen that includes：\n\n1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine).\n2. GT101 infusion.\n3. post-infusion treatment (interleukin-2 intravenous push).",[27],"2026-04-13",{"date":168,"type":32},"2026-04-14",{"date":170,"type":32},"2022-05-23",{"date":172,"type":21},"2026-06-30",{"name":174,"class":39},"Grit Biotechnology",5,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},"100623434","phase-1-hmpl-a580-in-participants-with-advanced-or-metastatic-solid-tumor-100623434","NCT07396584","HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","A Phase I\u002FⅡa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Understood this study and are able to voluntarily sign the informed consent form (ICF);\n2. Male or Female, Age ≥ 18 years;\n3. Histological confirmed, unresectable, advanced or metastatic solid tumor\n4. Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1\n5. Life expectancy ≥ 12 weeks\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n\nExclusion Criteria:\n\n1. An established diagnosis of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus\n2. Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug\n3. Major surgery within 28 days prior to the first dose of study drug\n4. Active infection requiring systemic treatment\n5. Participant has received a live within 3 months before study enrollment\n6. History of inflammatory gastrointestinal diseases\n7. Known hypersensitivity to any component of HMPL-A580\n8. Pregnant (positive pregnancy test) or lactating;",{"count":184,"type":21},186,[24,52],"This is a first-in-human, multicenter, open-label, phase I\u002FⅡa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.",[27],"2026-03-24",{"date":190,"type":32},"2026-03-27",{"date":192,"type":21},"2026-03-04",{"date":194,"type":21},"2029-01-30",{"name":151,"class":39},11,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":130},"100625019","phase-1-a-phase-iii-study-of-absk141-in-patients-with-advanced-solid-tumors--absk141-101--100625019","NCT07417189","A Phase I\u002FII Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","A Phase I\u002FII, Open-Label Study of ABSK141 to Assess Safety, Tolerability, Efficacy and Pharmacokinetics in Patients With KRAS G12D Mutant Advanced Solid Tumors","Inclusion Criteria:\n\n1. Patients should understand, sign, and date the written informed consent form prior to screening\n2. Male or female age 18 years or older\n3. Patients with histologically confirmed locally-advanced or metastatic solid tumors .\n\nFor backfill cohorts in the escalation part:\n\n1. Patients must have the following solid tumor harboring KRAS G12D mutation:\n\n   1. Colorectal cancer (CRC);\n   2. Non-small cell lung cancer (NSCLC);\n   3. Pancreatic ductal adenocarcinoma (PDAC);\n2. Patients must have at least one measurable target lesion according to RECIST 1.1\n\nFor expansion Part:\n\n1. Patients must have the following solid tumor harboring KRAS G12D mutation:\n\n   1. Colorectal cancer (CRC);\n   2. Non-small cell lung cancer (NSCLC);\n   3. Pancreatic ductal adenocarcinoma (PDAC);\n   4. Other solid tumors;\n2. Patients must have at least one measurable target lesion according to RECIST 1.1\n\nFor phase II:\n\n1. Patients with locally advanced or metastatic solid tumors confirmed by histological examination, whose disease has progressed after standard treatment or who are intolerant to standard treatment, or for whom there is currently no standard treatment.\n2. Patients must have the following solid tumor harboring KRAS G12D mutation:\n\n   1. Colorectal cancer (CRC);\n   2. Non-small cell lung cancer (NSCLC);\n   3. Pancreatic ductal adenocarcinoma (PDAC);\n   4. Other solid tumors;\n3. Patients must have at least one measurable target lesion according to RECIST 1.1 4. ECOG performance status 0 or 1 5. Adequate organ function and bone marrow function as indicated by the following screening assessments performed within 14 days prior to the first dose of study drug 6. For patients participating exploration of food effect:\n\n(1) be able to eat a standardized high-fat, high caloric meal within 30 minutes (2) be able to fast for 10 hours\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to any component of the investigational product\n2. (For backfill cohorts and expansion part) Patients who were previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy\n3. Has a known additional malignancy that is progressing or has required active treatment\n4. Unable to swallow capsules or tablets or malabsorption syndrome, disease significantly affecting GI function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction. If any of these conditions exist, the site should discuss with the sponsor to determine patient eligibility\n5. Previous anti-tumor therapy, including chemotherapy, endocrine therapy, molecular targeted therapy or other investigational drugs received ≤2 weeks or ≤5-half life (whichever is shorter), radiotherapy and antibody therapy received ≤4 weeks prior to initiation of study treatment\n6. Major surgery within 4 weeks of the first dose of study drug. Note that all surgical wounds must be healed and free of infection or dehiscence\n7. Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy, that have not regressed to Grade ≤1 severity (CTCAE v5.0)\n8. Patients should not use proton pump inhibitors for at least 7 days prior to the first dose of ABSK141 and during treatment with ABSK141.\n9. P-gp inhibitor and strong CYP3A inhibitors to 7 days or 5 half-lives whichever is longer and for CYP3A inducers to 2 weeks or 5 half-lives\n10. Active central nervous system (CNS) metastases\n11. History of interstitial lung disease requiring systemic steroid treatment.\n12. Impaired cardiac function or clinically significant cardiac disease\n13. NSCLC cohorts: Patient previously identified as having a driver mutation (according to local standard of care or guidelines) and have not received any targeted therapy, for example: EGFR mutation, ALK rearrangement, KRAS G12C mutation, NTRK1\u002F2\u002F3 gene fusion, RET fusion, MET exon14 skipping mutation, BRAF V600E mutation, ROS1 rearrangement, etc\n14. Known acquired immunodeficiency syndrome (AIDS)-related illness, or positive test for HIV 1\u002F2 antibody\n15. Exclusion of hepatitis infection\n16. Patients with refractory\u002Funcontrolled ascites or pleural effusion\n17. Pregnant or nursing (lactating) women\n18. refuse to use highly effective methods of birth control during the study and for up to 6 months after the last dose of study drug.\n19. Sexually active males who refuse to use a condom during intercourse while taking drug and for 5 consecutive compound half-lives plus 60 days after stopping study drug.\n20. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first dose of study treatment except for administration of inactivate vaccines\n21. Planned major surgery during study treatment\n22. Any other clinically significant comorbidities",{"count":205,"type":21},401,[24,52],"This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I\u002FII study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.",[27],[210,211],"ABSK141","KRAS G12D","2026-03-09",{"date":214,"type":32},"2026-03-11",{"date":216,"type":32},"2026-03-02",{"date":218,"type":21},"2029-07-30",{"name":220,"class":39},"Abbisko Therapeutics Co, Ltd",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":233,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100612682","phase-1-a-study-of-gc203-til-in-advanced-solid-tumors-nf-100612682","NCT07256756","A Study of GC203 TIL in Advanced Solid Tumors (NF)","A Phase I Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* have one the tumor resection for gene-edited GC203 TIL production and successfully produced；\n* Age: 18 years to 75years;\n* Histologically diagnosed as solid tumor;\n* Expected life-span more than 3 months;\n* ECOG score 0-1;\n* Test subjects have failed standard treatment regimens, and be willing to receive engineered GC203 TIL therapy;\n* At least 1 evaluable tumor lesion;\n\nExclusion Criteria:\n\n* with other malignant tumors,except for the malignancies that have been cured, have been inactive for ≥5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;\n* Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is \\\u003C 95%;\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;\n* Significant cardiovascular anomalies",{"count":229,"type":21},8,[24],"This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.",[27],"NOT_YET_RECRUITING",{"date":235,"type":32},"2025-12-23",{"date":237,"type":21},"2026-01-30",{"date":239,"type":21},"2028-11-30",{"name":241,"class":39},"Shanghai Juncell Therapeutics",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":257,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":270},"100507446","phase-1-study-of-tng260-and-an-anti-pd-antibody-in-stk11-mutated-solid-tumors-100507446","NCT05887492","Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","A Phase 1\u002F2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors","Inclusion Criteria:\n\n* Is ≥18 years of age at the time of signature of the main study ICF.\n* Has ECOG performance status of 0 or 1.\n* Has measurable disease based on RECIST v1.1.\n* All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytical method\n* Has confirmed histologic or cytologic diagnosis of a locally advanced or metastatic solid tumor.\n* Adequate organ function\u002Freserve per local labs\n* Adequate liver function per local labs\n* Adequate renal function per local labs\n* Negative serum pregnancy test result at screening\n* Written informed consent must be obtained according to local guidelines\n\nExclusion Criteria:\n\n* Known allergies, hypersensitivity, or intolerance to TNG260, PD-1 antibody or its excipients\n* Uncontrolled intercurrent illness that will limit compliance with the study requirements\n* Active infection requiring systemic therapy\n* Currently participating in or has planned participation in a study of another investigational agent or device\n* Impairment of GI function or disease that may significantly alter the absorption of oral TNG260\n* Active prior or concurrent malignancy.\n* Central nervous system metastases associated with progressive neurological symptoms\n* Current active liver disease from any cause\n* Clinically relevant cardiovascular disease\n* A female patient who is pregnant or lactating",{"count":250,"type":21},126,[24,52],"The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation.\n\nThe main question\\[s\\] it aims to answer are:\n\n* the recommended dose for Phase 2\n* to evaluate the safety and tolerability of the combination therapy\n* to determine the pharmacokinetics of TNG260\n* to evaluate the initial antineoplastic activity\n\nParticipants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.",[254,27,255,256],"Non Small Cell Lung Cancer","Lung Cancer","Lung Adenocarcinoma",[258,259,260],"STK11","KRAS wild type","LKB1","2025-11-14",{"date":263,"type":32},"2025-11-18",{"date":265,"type":32},"2023-06-12",{"date":267,"type":21},"2026-06",{"name":269,"class":39},"Tango Therapeutics, Inc.",13,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":40},"100554844","phase-1-safety-tolerability-and-pharmacokinetics-of-dcr-pdl1-in-adults-with-solid-tumors-100554844","NCT06504368","Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors","An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors","Inclusion Criteria:\n\n* Male or female adults, aged greater than or equal to (≥) 18 years.\n* Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma\n\n  * that is refractory to standard therapy known to provide clinical benefit for their condition OR\n  * have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR\n  * have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR\n  * for which no standard therapy is available\n* Measurable disease according to RECIST version 1.1.\n* Malignancy not currently amenable to surgical intervention.\n* ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months at the time of signing the informed consent.\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants with known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.\n* Other protocol defined exclusion criteria could apply",{"count":279,"type":21},32,[24],"The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.",[27],"2025-11-04",{"date":285,"type":32},"2025-11-06",{"date":287,"type":32},"2024-05-29",{"date":289,"type":21},"2027-12-31",{"name":291,"class":39},"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":160,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":130},"100522888","phase-1-til-injection-for-the-treatment-of-metastatic-or-recurrent-solid-tumors-100522888","NCT06088472","TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","A Single-arm Phase I Clinical Study of TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","Inclusion Criteria:\n\n* 1\\. Voluntarily participate in the study, sign the informed consent form, and be willing and able to follow the study protocol ;\n* 2.Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies: unresectable recurrent or metastatic solid tumor;\n* 3.At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies, and at least tissue blocks with a volume of≥0.5 cubic centimeter (either of single lesion origin or multiple lesions combined) can be isolated for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible;\n\nExclusion Criteria:\n\n* 1\\. Patients who have symptomatic and\u002For untreated CNS metastases (Except stable brain metastases, no medication required within 3 months, no hormone dependence);\n* 2.The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\\>10 mg\u002Fday of prednisone or equivalent hormone) within 14 days before lymphocyte depletion chemotherapy;\n* 3\\. Arterial\u002Fvenous thrombotic events within 6 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring;\n* 4.Active infections requiring treatment with systemic anti-infectives (except for topical antibiotics); or those with unexplained fever \\> 38.5℃ occurring during the screening period, except for tumor fever;\n* 5\\. Patients who have refractory or intractable epilepsy, hydrops abdominis, active gastrointestinal bleeding or IL-2 contraindications;\n* 6\\. Patients who have received allogeneic bone marrow transplantation or an organ allograft;\n* 7.Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin);",{"count":300,"type":21},12,[24],"This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.",[27],"2025-09-23",{"date":306,"type":32},"2025-09-29",{"date":308,"type":32},"2021-04-21",{"date":289,"type":21},{"name":174,"class":39},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":322,"phases":4,"briefSummary":323,"conditions":324,"keywords":327,"overallStatus":233,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":130},"100586520","granzyme-b-targeted-pet-imaging-monitoring-tumor-responses-to-immunotherapy-100586520","NCT06916442","Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy","A Single-Arm, Open-Label, Exploratory Study of Granzyme B-Targeted PET Imaging for Evaluating Tumor Response to Immunotherapy in Solid Tumors","GZMB_PET","Inclusion Criteria\n\n1. Voluntarily participate and sign the written informed consent form.\n2. Aged 18 to 90 years (inclusive), regardless of gender.\n3. Treatment-naïve patients with pathologically confirmed malignant solid tumors scheduled to receive immunotherapy.\n4. Willing and able to adhere to scheduled visits, treatment plans, and laboratory tests.\n\nExclusion Criteria\n\n1. Pregnant or lactating patients.\n2. Patients with a known allergy to GZMB-targeted imaging agents or synthetic excipients.\n3. Fasting blood glucose level exceeding 11.0 mmol\u002FL prior to 18F-FDG administration.\n4. Patients unable to undergo PET\u002FCT imaging (e.g., inability to lie supine, claustrophobia, severe anxiety related to radiation exposure).\n5. Patients with poor compliance or other factors deemed by the investigator to preclude participation in the study.","90 Years",{"count":321,"type":21},200,"OBSERVATIONAL","Malignant solid tumors, characterized by their persistently high incidence and mortality rates, pose a significant threat to human health and life, imposing a substantial societal burden. Molecular imaging enables the non-invasive, in vivo visualization of tumorigenesis and progression at the molecular level. Compared to traditional morphology-based imaging techniques, molecular imaging provides more precise information for early tumor diagnosis, treatment efficacy assessment, and clinical disease management. 18F-FDG PET\u002FCT imaging is currently the most widely used molecular imaging modality. However, under immunotherapy, FDG accumulates extensively in activated T cells, leading to increased false-positive evaluations. It fails to effectively distinguish metabolic hyperactivity between proliferative tumor cells (indicative of true progressive disease) and infiltrating immune cells (associated with pseudoprogression), thereby complicating the assessment of immunotherapy efficacy. Therefore, exploring novel molecular imaging probes with high specificity is of critical importance for patients undergoing tumor immunotherapy, as it can lead to more accurate evaluation of treatment efficacy. Granzyme B (GZMB), a serine protease released from cytoplasmic granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, induces apoptosis in target cells, particularly tumor cells-a central mechanism of tumor immunotherapy. This makes GZMB a promising molecular target for evaluating immunotherapy efficacy. This study aims to assess tumor immunotherapy outcomes using GZMB-targeted PET imaging and compare its performance with 18F-FDG PET\u002FCT. The goal is to achieve timely and accurate efficacy evaluation and longitudinal monitoring, identify potential beneficiaries, optimize clinical decision-making, and ultimately deliver personalized precision treatment to improve overall treatment outcomes.",[325,27,326],"PET\u002FCT","Solid Tumors, Advanced Solid Tumors",[328,329,330,331],"Granzyme B","PET Imaging","Immunotherapy Response","Diagnostic Efficacy","2025-03-31",{"date":334,"type":32},"2025-04-08",{"date":336,"type":21},"2025-04-01",{"date":289,"type":21},{"name":339,"class":129},"Zhongnan Hospital",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":130},"100585043","phase-1-pank-003-cell-injection-combined-with-standard-adjuvant-chemotherapy-after-surgery-in-patients-with-solid-tumors-100585043","NCT06897228","PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors","A Single-center, Single-arm, Dose-escalation Exploratory Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors","Inclusion Criteria:\n\n1. Understand and voluntarily sign the informed consent form;\n2. At the time of screening, the age should be between 18 and 75 years old (inclusive), regardless of gender;\n3. Patients who have been histologically confirmed or diagnosed by imaging (computed tomography (CT) examination, magnetic resonance imaging (MRI) examination or positron emission tomography (PET) scan CT (PET\u002FCT)) as postoperative patients with malignant solid tumors;\n4. Patients who have undergone surgical treatment and are going to receive or are currently undergoing postoperative adjuvant chemotherapy;\n5. At the time of enrollment, the expected survival time is more than 6 months;\n6. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;\n7. At the time of screening, the laboratory tests should meet the following requirements:\n\n   * White blood cell count ≥ 3.0×10⁹\u002FL;\n   * Neutrophil count ≥ 1.5×10⁹\u002FL;\n   * Lymphocyte count ≥ 0.5×10⁹\u002FL;\n   * Hemoglobin ≥ 90 g\u002FL;\n   * Platelets ≥ 75×10⁹\u002FL;\n   * Serum total bilirubin ≤ 2.0× the upper limit of normal value (ULN). For patients with a history of Gilbert's syndrome\u002Fsuspected of having the disease, the total bilirubin (TBIL) should be ≤ 3×ULN;\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN;\n   * Creatinine \\\u003C 1.5×ULN and endogenous creatinine clearance rate ≥ 50 mL\u002Fminute (Cockcroft-Gault method for calculating creatinine clearance rate: For men, creatinine clearance rate = \\[(140 - age) × body weight (kg)\\] \u002F \\[0.818 × creatinine (μmol\u002FL)\\]; For women, creatinine clearance rate = \\[(140 - age) × body weight (kg) × 0.85\\] \u002F \\[0.818 × creatinine (μmol\u002FL)\\]);\n8. Good lung function, with a baseline fingertip pulse oximetry saturation ≥ 95% in an indoor air environment;\n9. Female subjects of childbearing age must undergo a serum pregnancy test at the time of screening with a negative result, and be willing to use a medically approved highly effective contraceptive method during the study period and for at least 1 year after the last study treatment. For male subjects whose partners are of childbearing age, they should have undergone surgical sterilization or agree to use an effective contraceptive method during the study period and for at least 1 year after the last study treatment;\n10. Be evaluated by the investigator as suitable for inclusion in this clinical study.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Individuals with a history of allergy to any component of the cell product;\n3. Patients with other malignant tumors, except for the following situations: cured non-melanoma skin cancer, in-situ cervical cancer, localized prostate cancer, superficial bladder cancer, and other malignant tumors with a disease-free survival period of more than 5 years;\n4. Positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B e antigen (HBeAg), positive for hepatitis B e antibody (HBe-Ab) and\u002For hepatitis B core antibody (HBc-Ab), and the HBV-DNA copy number is greater than the lower limit of measurability; positive for hepatitis C antibody (HCV-Ab); positive for Treponema pallidum antibody (TP-Ab); positive for human immunodeficiency virus (HIV) antibody test; anyone meeting any one of these items;\n5. Patients who have received drugs from other clinical trials or other cellular immunotherapies within 28 days before the screening period;\n6. Those who have received live vaccines or live attenuated vaccines within 4 weeks before NK cell infusion;\n7. Patients with comorbidities that, in the judgment of the investigator, require treatment with systemic corticosteroids or other immunosuppressive drugs during the study period;\n8. Individuals with a high allergic constitution, those allergic to any component of the NK preparation product, including those allergic to serum albumin; those allergic to commonly used emergency and anesthetic drugs;\n9. Having any unstable circulatory system diseases within 180 days before screening, including but not limited to unstable angina pectoris, myocardial infarction, heart failure \\[New York Heart Association (NYHA) class ≥ III\\], severe arrhythmia requiring drug treatment, or having undergone angioplasty, coronary artery stent implantation, or coronary artery bypass grafting within 180 days before screening;\n10. Diseases or other situations that the investigator deems unsuitable for this clinical study (such as high allergic constitution, poorly controlled diabetes mellitus, uncontrolled infections, presence of central nervous system diseases, bleeding and thrombotic tendencies; as well as poor compliance, drug abuse, etc.).",{"count":348,"type":21},18,[24],"A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy after surgery in patients with solid tumors",[27],"2025-03-20",{"date":354,"type":32},"2025-03-26",{"date":356,"type":32},"2024-02-18",{"date":358,"type":21},"2027-03",{"name":360,"class":39},"Shenzhen Celconta Life Science Co., Ltd.",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":380,"locationsCount":130},"100547173","low-dose-chemotherapy-under-hypoglycaemia-for-the-treatment-of-relapsed-refractory-advanced-solid-tumours-100547173","NCT06404528","Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours","A Clinical Study on the Efficacy and Mechanism of Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours","Inclusion Criteria:\n\n1. Male or female aged 18-75 years;\n2. ASubjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;\n3. Subjects have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);\n4. ECOG score of 0-2, lifespan \\> 12 weeks;\n5. Women of childbearing age who have a negative pregnancy test within 7 days before treatment. Female patients of childbearing age, and male patients with partners of childbearing age must agree to use at least one medically recognized contraceptive method during study treatment and within at least 6 months after the last dose of investigational drug;\n6. Voluntarily participated in this study, signed the informed consent form, had good compliance, and cooperated with the follow-up\n\nExclusion Criteria:\n\n1. The patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid);\n2. White blood cell count ≥ 50×10\\^9\u002F L or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle;\n3. Patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment.\n4. HIV, HBV and HCV positive;\n5. Patients with diseases of the central nervous system or autoimmune central nervous system lesions, Including stroke, epilepsy, dementia;\n6. Patients have myocardial infection, cardiac angiography or stents, active angina or other obvious clinical symptoms, or have cardiopathic asthma or cardiovascular lymphocytic infiltrates，within 12 months;\n7. Patients are on anticoagulation or have severe coagulopathy (APTT\\>70);\n8. Patients in any condition requiring systemic treatment with corticosteroids or other immunosuppressive agents within 2weeks prior to investigational drug administration;\n9. Patients were infected with covid-19 within 2weeks prior to investigational drug administration;\n10. Subjects having any serious uncontrolled disease or in other conditions that would preclude them from receiving study treatment and are considered unsuitable for this study in the opinion of the investigator;\n11. Subjects in other conditions that are considered unsuitable for this study by the investigator.-",{"count":369,"type":21},300,[371],"NA","By controlling the patient's blood sugar, small doses of chemotherapy are used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, and produce very strong anticancer effects without the cytotoxic effects of chemotherapy.",[27],"2024-05-06",{"date":376,"type":32},"2024-05-08",{"date":378,"type":32},"2023-09-04",{"date":149,"type":21},{"name":381,"class":129},"Wuxi People's Hospital"]